BR0010823A - Adjuvante de estabilidade, biocompatibilidade otimizada (sba) para realçar a resposta imune humoral e celular - Google Patents

Adjuvante de estabilidade, biocompatibilidade otimizada (sba) para realçar a resposta imune humoral e celular

Info

Publication number
BR0010823A
BR0010823A BR0010823-5A BR0010823A BR0010823A BR 0010823 A BR0010823 A BR 0010823A BR 0010823 A BR0010823 A BR 0010823A BR 0010823 A BR0010823 A BR 0010823A
Authority
BR
Brazil
Prior art keywords
sba
immune response
cellular immune
humoral
enhance
Prior art date
Application number
BR0010823-5A
Other languages
English (en)
Inventor
Rainer Helmut Mueller
Nikolaus Grubhofer
Carsten Olbrich
Original Assignee
Pharmasol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasol Gmbh filed Critical Pharmasol Gmbh
Publication of BR0010823A publication Critical patent/BR0010823A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção: "ADJUVANTE DE ESTABILIDADE, BIOCOMPATIBILIDADE OTIMIZADA (SBA) PARA REALçAR A RESPOSTA IMUNE HUMORAL E CELULAR". A invenção refere-se a um adjuvante de estabilidade e biocompatibilidade otimizada (SBA) para realçar a resposta imune humoral e celular no caso de injeção junto com um ou mais antígenos. O adjuvante consiste em partículas com base em lipídeos sólidos ou misturas de lipídeos sólidos. Aplicações possíveis incluem a produção de vacinas mais eficazes e melhor toleradas, vacinações de seres humanos e animais e também a produção de anticorpos. Através da escolha de tamanho de partícula, carga de partícula e propriedades da superfície, a intensidade da resposta imune pode ser especificamente modulada e adicionalmente ajustada para ser específica das espécies. Outros adjuvantes, por exemplo adjuvantes moleculares tal como GMDP podem ser adicionados ao SBA, adicionalmente aumentando a resposta imune celular. O SBA é eficaz e económico, mais simples para manuseio do que os produtos existentes e é bem tolerado in vivo.
BR0010823-5A 1999-05-20 2000-05-19 Adjuvante de estabilidade, biocompatibilidade otimizada (sba) para realçar a resposta imune humoral e celular BR0010823A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19923256 1999-05-20
PCT/EP2000/004565 WO2000071154A2 (de) 1999-05-20 2000-05-19 Stabilitäts-, biokompatibilitäts-optimiertes adjuvans (sba) zur erhöhung der humoralen und zellulären immunantwort

Publications (1)

Publication Number Publication Date
BR0010823A true BR0010823A (pt) 2002-03-05

Family

ID=7908697

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010823-5A BR0010823A (pt) 1999-05-20 2000-05-19 Adjuvante de estabilidade, biocompatibilidade otimizada (sba) para realçar a resposta imune humoral e celular

Country Status (11)

Country Link
EP (1) EP1183045A2 (pt)
JP (1) JP2003500365A (pt)
KR (1) KR20020012221A (pt)
AU (2) AU5214200A (pt)
BR (1) BR0010823A (pt)
CA (1) CA2373239A1 (pt)
DE (1) DE10024788A1 (pt)
MX (1) MXPA01011660A (pt)
TR (1) TR200103333T2 (pt)
WO (2) WO2000071154A2 (pt)
ZA (1) ZA200109147B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2373239A1 (en) * 1999-05-20 2000-11-30 Pharmasol Gmbh Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
CA2542777C (en) * 2003-10-23 2016-02-02 Chiron Corporation Stabilised compositions
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
KR102584844B1 (ko) 2009-06-12 2023-10-04 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
AU2013256565B2 (en) 2012-04-30 2015-12-03 Ossur Hf Prosthetic device, system and method for increasing vacuum attachment
KR102264177B1 (ko) 2012-07-12 2021-06-11 맨카인드 코포레이션 건조 분말 약물 전달 시스템 및 방법
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US20180318415A1 (en) * 2015-12-08 2018-11-08 Glaxosmithkline Biologicals, Sa Novel adjuvant formulations
CN114428171A (zh) * 2020-10-29 2022-05-03 深圳迈瑞生物医疗电子股份有限公司 检测甘胆酸的试剂盒、方法及用途
KR102721917B1 (ko) * 2022-05-31 2024-11-04 우리이앤엘 주식회사 비타민 함유 리포좀의 제조 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
JP2002521423A (ja) * 1998-07-31 2002-07-16 コリア インスティチュート オブ サイエンス アンド テクノロージ 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子
CA2373239A1 (en) * 1999-05-20 2000-11-30 Pharmasol Gmbh Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response

Also Published As

Publication number Publication date
WO2000071154A3 (de) 2001-06-28
WO2000071154A2 (de) 2000-11-30
AU5214200A (en) 2000-12-12
CA2373239A1 (en) 2000-11-30
KR20020012221A (ko) 2002-02-15
MXPA01011660A (es) 2004-04-05
TR200103333T2 (tr) 2002-04-22
EP1183045A2 (de) 2002-03-06
WO2000071077A2 (de) 2000-11-30
DE10024788A1 (de) 2000-11-23
AU5809100A (en) 2000-12-12
ZA200109147B (en) 2002-05-08
JP2003500365A (ja) 2003-01-07

Similar Documents

Publication Publication Date Title
BR0010823A (pt) Adjuvante de estabilidade, biocompatibilidade otimizada (sba) para realçar a resposta imune humoral e celular
ATE229978T1 (de) Helicobacter proteine und impstoffe
NO20015073D0 (no) Vaksiner
DE69030172D1 (de) Impfstoffe gegen Krebs und Infektionskrankheiten
ATE461709T1 (de) Choline-bindende proteine derivate aus pneumokoken als impfstoff
DE69939747D1 (de) Verfahren von dna-impfung
ITFI920052A1 (it) Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
PT1135166E (pt) Conjugados de hapteno-veiculo para o tratamento e prevencao da dependencia a nicotina
DK1140165T3 (da) Fordbedrede adjuvanssammensætninger baseret på saponin og dermed tilhörende metoder
EP1964573A3 (en) Method of inducing and/or enhancing an immune response to tumor antigens
DE60144240D1 (de) Zusammensetzung mit immunogenen mikroteilchen
BR0314373A (pt) Produto imunogênico estável para a indução de anticorpos contra uma ou várias proteìnas antigênicas em um indivìduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
DE60012042D1 (de) Entepneumovirus und entsprechendes impfstoff
BR0208041A (pt) Interferon beta modificado com imunogenicidade reduzida
DK0686030T3 (da) Med antigen ladede mikropartikler og farmaceutiske sammensætninger, som indeholder disse mikropartikler
WO2000012122A3 (de) Niedermolekulare fragmente der hyaluronsäure zur herstellung von impfstoffen
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
AR045416A1 (es) Coadyuvante de linfocitos humanos para vacunas
BRPI0409321A (pt) antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo
BR9306187A (pt) Vacina bacterin-toxóide pasteurella haemolytica tipo a-1
BR0207020A (pt) Fator de estimulação de colÈnia por granulócito (g-csf) modificado com imunogenicidade reduzida
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
Lovgren Construction and potential of the iscom as immunogen.
BR0110791A (pt) Composição, métodos para induzir uma resposta imune em um indivìduo contra um imunogene, para modular o sistema imune de um indivìduo e para imunizar um indivìduo contra um patógeno, vacina recombinante, e patógeno atenuado vivo
BR0208120A (pt) Insulina modificada com imunogenicidade reduzida

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.